Ipilimumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ipilimumab" in French language version.

refsWebsite

Global rank French rank

5nejm.org

2,374^th place

298^th place

2sciencedirect.com

149^th place

80^th place

2ascopubs.org

low place

7,741^st place

2wiley.com

222^nd place

129^th place

1qmul.ac.uk

1,735^th place

168^th place

1issn.org

57^th place

4^th place

1newyorker.com

146^th place

429^th place

1bmsfrance.fr

low place

1liebertpub.com

low place

4,955^th place

1ovid.com

low place

7,922^nd place

1has-sante.fr

9,562^nd place

535^th place

ascopubs.org

Weber JS, Kähler KC, Hauschild A, Management of immune‐related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 2012;30:2691–7
Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T‐lymphocyte‐associated antigen 4, J Clin Oncol, 2006;24:2283–9

bmsfrance.fr

http://www.bmsfrance.fr/nos-medicaments/Documents/YERVOY/AT_Yervoy_06-11-2013.pdf

has-sante.fr

http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-01/yervoy_14_12_2011_avis_ct_11462.pdf

issn.org

portal.issn.org

Jerome Groopman, « The T-Cell Army », The New Yorker,‎ 23 avril 2012 (ISSN 0028-792X, lire en ligne, consulté le 7 mars 2016)

liebertpub.com

Minor DR, Chin K, Kashani‐Sabet M, Infliximab in the treatment of anti‐CTLA4 antibody (ipilimumab) induced immune‐related colitis, Cancer Biother Radiopharm, 2009;24:321–5

nejm.org

Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade, N Engl J Med, 2016;375:1749–55
Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 2010;363:711-723
Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 2011;364:2517-2526
Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus Ipilimumab in advanced melanoma, N Engl J Med, 2013;369:122-133
Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 2018;378:1277-1290

newyorker.com

Jerome Groopman, « The T-Cell Army », The New Yorker,‎ 23 avril 2012 (ISSN 0028-792X, lire en ligne, consulté le 7 mars 2016)

ovid.com

insights.ovid.com

Mitchell KA, Kluger H, Sznol M, Hartman DJ, Ipilimumab‐induced perforating colitis, J Clin Gastroenterol, 2013;47:781–5

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sciencedirect.com

Michot JM, Bigenwald C, Champiat S et al. Immune‐related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer, 2016;54:139–48
Verschuren EC, van den Eertwegh AJ, Wonders J et al. Clinical, endoscopic, and histologic characteristics of ipilimumab‐associated colitis, Clin Gastroenterol Hepatol, 2016;14:836–42

wiley.com

onlinelibrary.wiley.com

Adler BL, Pezhouh MK, Kim A et al. Histopathological and immunophenotypic features of ipilimumab‐associated colitis compared to ulcerative colitis, J Int Med, 2018;283:568-577
Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival, Cancer, 2010;116:1767-1775